Cholic Acid for Hepatic Steatosis in Lipodystrophy
Phase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy Patients
Sponsor: FDA Office of Orphan Products Development
A PHASE2 clinical study on Hepatic Steatosis, this trial is completed. The trial is conducted by FDA Office of Orphan Products Development and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- FDA Office of Orphan Products Development
- University of Texas Southwestern Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .